14.58
price down icon6.54%   -1.02
after-market Dopo l'orario di chiusura: 14.71 0.13 +0.89%
loading
Precedente Chiudi:
$15.60
Aprire:
$15.63
Volume 24 ore:
1.01M
Relative Volume:
0.94
Capitalizzazione di mercato:
$728.33M
Reddito:
-
Utile/perdita netta:
$-156.39M
Rapporto P/E:
-3.9512
EPS:
-3.69
Flusso di cassa netto:
$-123.06M
1 W Prestazione:
-5.26%
1M Prestazione:
+24.83%
6M Prestazione:
+69.34%
1 anno Prestazione:
+1.32%
Intervallo 1D:
Value
$14.48
$15.63
Intervallo di 1 settimana:
Value
$14.48
$15.97
Portata 52W:
Value
$7.30
$16.32

Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile

Name
Nome
Kalvista Pharmaceuticals Inc
Name
Telefono
(857) 999-0075
Name
Indirizzo
55 CAMBRIDGE PARKWAY, CAMBRIDGE, MA
Name
Dipendente
270
Name
Cinguettio
@kalvista
Name
Prossima data di guadagno
2025-03-12
Name
Ultimi documenti SEC
Name
KALV's Discussions on Twitter

Confronta KALV con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Biotechnology icon
KALV
Kalvista Pharmaceuticals Inc
14.58 779.28M 0 -156.39M -123.06M -3.69
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
469.65 121.28B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
563.10 60.96B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
328.81 42.77B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
591.99 36.21B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
291.47 32.08B 3.81B -644.79M -669.77M -6.24

Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-01-31 Iniziato JMP Securities Mkt Outperform
2025-01-07 Iniziato TD Cowen Buy
2024-12-18 Iniziato BofA Securities Buy
2020-06-15 Iniziato H.C. Wainwright Buy
2019-07-29 Iniziato SVB Leerink Outperform
2019-03-20 Iniziato Needham Buy
2018-10-30 Iniziato Jefferies Buy
2018-09-21 Iniziato Cantor Fitzgerald Overweight
2017-08-31 Iniziato BTIG Research Buy
Mostra tutto

Kalvista Pharmaceuticals Inc Borsa (KALV) Ultime notizie

pulisher
Jul 25, 2025

EMA’s CHMP adopts five orphans - biocentury.com

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about KalVista Pharmaceuticals Inc. stock outlookPhenomenal capital gains - jammulinksnews.com

Jul 25, 2025
pulisher
Jul 25, 2025

New medicines recommended for approval by EMA’s CHMP - The Pharma Letter

Jul 25, 2025
pulisher
Jul 25, 2025

What analysts say about KalVista Pharmaceuticals Inc. stockFree Daily Trading Room Entry - Autocar Professional

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista receives CHMP opinion recommending sebetralstat marketing authorization - TipRanks

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista, Biogen, Ionis get EU positive opinions for key drugs (KALV:NASDAQ) - Seeking Alpha

Jul 25, 2025
pulisher
Jul 25, 2025

European regulator recommends approval of first oral HAE treatment - Investing.com India

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista Pharma Announces Positive CHMP Opinion For Sebetralstat - Nasdaq

Jul 25, 2025
pulisher
Jul 25, 2025

KalVista Pharmaceuticals Receives Positive CHMP Opinion for Sebetralstat for the Treatment of Hereditary Angioedema Attacks - Business Wire

Jul 25, 2025
pulisher
Jul 25, 2025

What drives KalVista Pharmaceuticals Inc. stock priceFree Daily Trading Room Entry - PrintWeekIndia

Jul 25, 2025
pulisher
Jul 24, 2025

US FDA Cancer Reviewers Heading For The Exits, Potentially Impacting Review Timelines - insights.citeline.com

Jul 24, 2025
pulisher
Jul 23, 2025

KalVista Pharmaceuticals Inc. Stock Analysis and ForecastRobust investment performance - jammulinksnews.com

Jul 23, 2025
pulisher
Jul 22, 2025

Is KalVista Pharmaceuticals Inc. a good long term investmentRapid return acceleration - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Friedreich's Ataxia Market Is Expanding Due To Advancing - openPR.com

Jul 21, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP By Investing.com - Investing.com South Africa

Jul 17, 2025
pulisher
Jul 17, 2025

Kalvista Pharmaceuticals stock maintains Market Outperform rating at JMP - Investing.com India

Jul 17, 2025
pulisher
Jul 16, 2025

(KALV) Proactive Strategies - news.stocktradersdaily.com

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval By Investing.com - Investing.com South Africa

Jul 16, 2025
pulisher
Jul 16, 2025

JMP reiterates Market Outperform rating on Kalvista stock after UK approval - Investing.com Nigeria

Jul 16, 2025
pulisher
Jul 16, 2025

KalVista Pharmaceuticals Announces UK MHRA Approval of EKTERLY® (sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - BioSpace

Jul 16, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Gets UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals announces UK MHRA approval of Ekterly (sebetralstat) - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista gets UK nod for Ekterly (KALV:NASDAQ) - Seeking Alpha

Jul 15, 2025
pulisher
Jul 15, 2025

UK approves first oral treatment for hereditary angioedema attacks By Investing.com - Investing.com Canada

Jul 15, 2025
pulisher
Jul 15, 2025

(sebetralstat), First and Only Oral On-demand Treatment for Hereditary Angioedema - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

MHRA approves Ekterly to treat HAE - The Pharma Letter

Jul 15, 2025
pulisher
Jul 15, 2025

KalVista Pharmaceuticals Wins UK Approval for Hereditary Angioedema Treatment - MarketScreener

Jul 15, 2025
pulisher
Jul 14, 2025

Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga

Jul 14, 2025
pulisher
Jul 13, 2025

Have Insiders Sold KalVista Pharmaceuticals Shares Recently? - simplywall.st

Jul 13, 2025
pulisher
Jul 13, 2025

The week in pharma: action, reaction and insight – week to July 11 - The Pharma Letter

Jul 13, 2025
pulisher
Jul 11, 2025

Kalvista stock maintains Buy rating at H.C. Wainwright on favorable Ekterly label - Investing.com Nigeria

Jul 11, 2025
pulisher
Jul 11, 2025

KalVista:HC Wainwright Raises PT to $27, Maintains Buy Rating - AInvest

Jul 11, 2025
pulisher
Jul 11, 2025

Kalvista Pharma chief development officer sells $474k in shares By Investing.com - Investing.com Canada

Jul 11, 2025
pulisher
Jul 10, 2025

KalVista Pharmaceuticals: EKTERLY Launch and Financial Update - TipRanks

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma chief development officer sells $474k in shares - Investing.com Australia

Jul 10, 2025
pulisher
Jul 10, 2025

Kalvista Pharma CEO Palleiko sells $517k in shares By Investing.com - Investing.com South Africa

Jul 10, 2025

Kalvista Pharmaceuticals Inc Azioni (KALV) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
$23.40
price down icon 0.97%
$36.67
price up icon 0.22%
$103.95
price up icon 0.42%
$28.67
price up icon 3.99%
$115.31
price up icon 0.65%
biotechnology ONC
$291.47
price down icon 1.68%
Capitalizzazione:     |  Volume (24 ore):